Audit 3311

FY End
2023-06-30
Total Expended
$47.40M
Findings
0
Programs
33
Organization: National Jewish Health (CO)
Year: 2023 Accepted: 2023-11-15
Auditor: Forvis LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.498 Covid-19 Provider Relief Fund (prf) and American Rescue Plan (arp) Rural Distribution $1.94M Yes 0
93.279 Drug Abuse and Addiction Research Programs $604,388 Yes 0
93.859 Biomedical Research and Research Training $434,947 Yes 0
93.855 Covid-19 Allergy, Immunology and Transplantation Research $237,197 Yes 0
93.257 Grants for Education, Prevention, and Early Detection of Radiogenic Cancers and Diseases $236,090 Yes 0
93.113 Covid-19 Environmental Health $230,159 Yes 0
93.387 National and State Tobacco Control Program (b) $182,000 - 0
47.074 Biological Sciences $134,560 Yes 0
93.866 Aging Research $118,723 Yes 0
93.838 Lung Diseases Research $115,262 Yes 0
93.855 Allergy, Immunology and Transplantation Research $102,030 Yes 0
93.840 Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders $83,244 Yes 0
93.310 Trans-Nih Research $81,222 Yes 0
93.113 Environmental Health $73,338 Yes 0
93.396 Cancer Biology Research $70,442 Yes 0
93.077 Family Smoking Prevention and Tobacco Control Act Regulatory Research $48,321 Yes 0
93.350 National Center for Advancing Translational Sciences $37,687 Yes 0
93.837 Cardiovascular Diseases Research $37,601 Yes 0
93.307 Minority Health and Health Disparities Research $36,316 Yes 0
27.011 Intergovernmental Personnel Act (ipa) Mobility Program $30,467 Yes 0
12.420 Military Medical Research and Development $22,984 Yes 0
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $19,790 Yes 0
93.838 Covid-19 Lung Diseases Research $19,036 Yes 0
93.233 National Center on Sleep Disorders Research $17,715 Yes 0
93.965 Coal Miners Respiratory Impairment Treatment Clinics and Services $17,511 - 0
93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health $11,136 Yes 0
93.493 Congressional Directives $8,525 Yes 0
93.846 Arthritis, Musculoskeletal and Skin Diseases Research $8,254 Yes 0
93.394 Cancer Detection and Diagnosis Research $7,728 Yes 0
93.U01 Covid-19 National Heart, Lung and Blood Institute $6,241 Yes 0
93.121 Oral Diseases and Disorders Research $3,356 Yes 0
93.103 Food and Drug Administration_research $2,745 Yes 0
93.262 Occupational Safety and Health Program $2,619 Yes 0

Contacts

Name Title Type
VLQKFEEJ3NE9 Michael Dickman Auditee
3033981866 Jami L. Johnson Auditor
No contacts on file

Notes to SEFA

Title: Basis of Presentation Accounting Policies: Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. De Minimis Rate Used: N Rate Explanation: National Jewish Health has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance and instead to use its federally approved indirect cost rate. The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of National Jewish Health and Subsidiary (National Jewish Health) under programs of the federal government for the year ended June 30, 2023. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of National Jewish Health, it is not intended to and does not present the consolidated statements of financial position, changes in net assets or cash flows of National Jewish Health.
Title: Summary of Significant Accounting Policies Accounting Policies: Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. De Minimis Rate Used: N Rate Explanation: National Jewish Health has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance and instead to use its federally approved indirect cost rate. Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.
Title: Indirect Cost Rate Accounting Policies: Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. De Minimis Rate Used: N Rate Explanation: National Jewish Health has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance and instead to use its federally approved indirect cost rate. National Jewish Health has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance and instead to use its federally approved indirect cost rate.